Full Press Release Details
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance
SPTX Positive Sentiment
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Key Takeaway: Seaport Therapeutics, a company founded by PureTech, has announced the dosing of the first patient in its Phase 2a clinical trial for GlyphAgo™. This trial aims to evaluate the efficacy of GlyphAgo™ in patients suffering from generalized anxiety disorder and sleep disturbances. The development marks a significant step forward in addressing these mental health challenges.
Market Sentiment Analysis
POSITIVE FACTORS
- First patient dosed in a Phase 2a clinical trial.
- Focus on treating generalized anxiety disorder and sleep disturbance.
- Potential for GlyphAgo™ to address significant health issues.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~29 mo
Minimal dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is GlyphAgo™ being tested for?
GlyphAgo™ is being evaluated for its efficacy in treating generalized anxiety disorder and sleep disturbance.
Who founded Seaport Therapeutics?
Seaport Therapeutics is a founded entity of PureTech.
What phase is the clinical trial for GlyphAgo™?
The clinical trial for GlyphAgo™ is currently in Phase 2a.
Where is Seaport Therapeutics based?
Seaport Therapeutics is based in Boston.